Cadonilimab
5 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix (NCT06810895) | Ding Ma | 2025-02-01 |
| Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer (NCT06367088) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2024-05-01 |
| NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC (NCT06405490) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-04-17 |
| Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases (NCT06265350) | Sun Yat-sen University | 2024-02-02 |
| Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer (NCT06218810) | Fudan University | 2024-01-01 |
Track Cadonilimab automatically
Every clearance here is in the API, with alerts when new ones post.